Export 60 results:
Autore [ Titolo(Desc)] Tipo Anno
Filtri: Autore è Zauli, Giorgio  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Gasparini C, Tommasini A, Zauli G. The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. Hum Immunol 2012;73(4):342-5.
Comar M, Cuneo A, Maestri I, Melloni E, Pozzato G, Soffritti O, Secchiero P, Zauli G. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. J Clin Virol 2012;55(4):367-9.
Secchiero P, Corallini F, Zavan B, Tripodo C, Vindigni V, Zauli G. Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Invest New Drugs 2012;30(2):803-7.
Zauli G, Voltan R, di Iasio MGrazia, Bosco R, Melloni E, Sana MElena, Secchiero P. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
Tisato V, Zauli G, Gianesini S, Menegatti E, Brunelli L, Manfredini R, Zamboni P, Secchiero P. Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction. J Immunol Res 2014;2014:473765.
Zauli G, Bosco R, Secchiero P. Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opin Ther Targets 2011;15(8):931-42.
N
Carinci F, Monasta L, Rubini C, Stramazzotti D, Palmieri A, Melloni E, Knowles A, Ronfani L, Zauli G, Secchiero P. The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. Invest New Drugs 2012;30(2):810-8.
Gasparini C, Celeghini C, Monasta L, Zauli G. NF-κB pathways in hematological malignancies. Cell Mol Life Sci 2014;71(11):2083-102.
di Iasio MGrazia, Zauli G. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells. Invest New Drugs 2013;31(2):458-60.
Simioni C, Cani A, Martelli AM, Zauli G, Alameen AAM, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 2015;6(19):17147-60.
O
Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.
Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, Secchiero P, Zauli G, Fabris B. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.

Amministrazione Trasparente